| abstract |
At least one chemical entity chosen from compounds of Formula (1) and pharmaceutically acceptable pharmaceutically acceptable salts, hydrates, solvates, crystal forms, diastereomers, and prodrugs thereof. Methods of treating or preventing disorders in which aberrant kinase activity is implicated, pharmaceutical compositions, and methods for detecting the presence kinases in cells or biological preparations and for identifying kinases of therapeutic interest. |